Monte Rosa Therapeutics, Inc. (GLUE)
After hours:
| Previous close | 5.65 |
| Open | 5.72 |
| Bid | 5.74 x 200 |
| Ask | 5.81 x 200 |
| Day's range | 5.57 - 5.91 |
| 52-week range | 2.44 - 8.84 |
| Volume | |
| Avg. volume | 139,623 |
| Market cap | 289.874M |
| Beta (5Y monthly) | 1.45 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.63 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 16.50 |
GlobeNewswireMonte Rosa Therapeutics Announces the Departure of Owen Wallace, Ph.D., Chief Scientific Officer
Dr. Wallace will depart his role as CSO effective May 17, 2024, and will serve as a scientific advisor, including on Monte Rosa’s Scientific Advisory BoardBOSTON, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that Owen Wallace, Ph.D., the Company’s Chief Scientific Officer will be departing from his position to transition to a Chief Execut
ZacksRecent Price Trend in Monte Rosa Therapeutics (GLUE) is Your Friend, Here's Why
Monte Rosa Therapeutics (GLUE) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
ZacksDoes Monte Rosa Therapeutics (GLUE) Have the Potential to Rally 107.79% as Wall Street Analysts Expect?
The consensus price target hints at a 107.8% upside potential for Monte Rosa Therapeutics (GLUE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
